



Publishing options: Dutch institution associated corresponding authors



1. Key definitions

Terminology	Definition
Submitting corresponding author	<p>Submitting corresponding author is the author who submits the article to Elsevier and stays in contact with Elsevier in the end-to-end journey</p> <p>This is the author who makes the publishing choice on behalf of the author group</p> <p>Every article has one corresponding author</p>
Submission Date	<p>This is the date the author submits the article for publication</p>
Elsevier OA Platform	<p>Elsevier OA Platform (EOAP) is a user-friendly interface where the institution can validate eligibility of authors, access the reporting showing articles activated under the agreement</p>

2. Eligibility criteria

Eligibility component	Description
Submission date	The submission date of the article should fall within the period of agreement for your institution
Author affiliation	<p>The submitting corresponding author must be affiliated with a participating institution in the agreement. Therefore, the institutional admin's validation of the author's eligibility is important.</p> <p>We rely on submitting corresponding authors declaring their affiliation as part of submission & post acceptance journeys.</p>
Journal title	The article must be submitted to and accepted in a participating journal.
Article type	The article type must be eligible. These are the OA article types that have peer reviewed content

3. Article types descriptions

PIT Codes	Article Type	Description
CRP	Case Report	A detailed report of the symptoms, diagnosis, treatment and follow-up of an individual patient.
DAT	Data in Brief	A short article that presents research data.
FLA	Full-length Article	A detailed study of original research.
MIC	Microarticle	A short publication; typically a brief description of original research.
OSP	Original Software Publication	An article that comprises computer code or software and a description thereof.
PRO	Protocol	A written procedure or guideline that provides a methodology for undertaking a specific piece of research.
REV	Review Article	An article that summarizes and reviews the current state of understanding of a topic.
RPL	Replication Study	An article that presents results of the replication of research performed previously and published elsewhere.
SCO	Short Communication	A short report or announcement of research, usually claiming certain results. (may appear under many names, E.g. Letter Papers, Preliminary Notes, Notes, etc)
SSU	Short Survey/Short Review	A short or mini Review Article, summarizing the current state of understanding of a topic.
VID	Video Article	An article that primarily consists of a video and a description of the content therein.

4. Agreement Overview (Current)

Journal Bucket	Agreement
Core Hybrid & Gold	The eligible submitting corresponding authors receive full APC coverage for unlimited APCs



Publishing Options

The author workflow



Publishing options at submission (Editorial Manager)

As part of the submission journey, once the author uploads the manuscript files, the corresponding author provides the affiliation details

em International Journal of Pharmaceutics

Home Main Menu Submit a Manuscript About Help

Please enter author details options and a personalized

Hint: start your institution return the most results from department, then selecting

You may reorder the author Current Author List.

Current Author List

Mr. Bharath

+ Add Another Author

+ Funding Information

Edit Author Details

[Corresponding Author] [First Author] [You]

Insert Special Characters

Your Given/First Name*

Middle Name

Your Family/Last Name*

Academic Degree(s)

Your E-mail Address* v.aradhyula@elsevier.com

ORCID Fetch/Register

What is ORCID?

Institution* University of Amsterdam

Country or Region

Contributor Roles*

- Amsterdam University of Applied Sciences Amsterdam, NL
- University of Amsterdam** Amsterdam Business School Amsterdam, NL
- University of Amsterdam** Faculty of Law Amsterdam, NL

← Back Save & Submit Later Build PDF for Approval →

The system presents information about the publishing options and informs the author that the choice they make at submission is an indication

Elsevier Publishing Options

Please indicate your Publishing Options

This is a hybrid journal. The journal publishes both subscription and OA articles. We will present your personalized Publishing Options based on the Affiliations and Funding details you have given us. Please note that at this stage in your submission, you are only indicating your preference. We will ask you to make a final choice after the journal has accepted your manuscript.

Publishing Options

Cancel

Proceed

The system presents personalized publishing options for the relevant agreement as the author has met all the eligibility criteria

Tell us how you want your work to be made available

Open access

Subscription not available

Agreement between The Netherlands and Elsevier

University of Amsterdam is part of this agreement. As a corresponding author affiliated with University of Amsterdam, you can publish open access at no cost. You must be accepted for publication by 31 December 2024. Contact us to [enquire about publishing as subscription](#).

[Read more about the agreement between The Netherlands and Elsevier](#)

Important information before you complete your submission

Availability and sharing of your article

If accepted for publication, your article will be made immediately available to everyone. It can be shared and reused in the ways described by the [Creative Commons end user license](#) you select.

Institutional and funder agreements

If accepted, any fees covered under agreements are subject to institution or funder approval, and fund availability. You may wish to check before proceeding.

Payment of open access fees

Open access fees only apply if accepted. Payment is your responsibility. If we invoice your institution and don't receive payment, or if fees covered under agreements are not approved, we will reissue the invoice to you. Or, if the journal allows it, you can choose to publish subscription at no cost to you.

Rights and access

If accepted, you must complete a publishing agreement to ensure we publish your article in the way you want. If the publishing agreement is not completed, we will apply a default Creative Commons end user license. Or, if the journal allows it, we will publish it as a subscription article.

If you don't agree to the above and to the full [Elsevier terms and conditions of purchase for open access services](#) you should not proceed with your submission.

Institution preferred
Your institution prefers you publish OA

To pay on acceptance

Only applicable if article accepted

	Price
⊖	EUR 4,240.00
APC	
🏛️	Institutional Agreement Discount
	-4,240.00
	<hr/>
👤	To pay (on validation)
	0.00

Publishing options after acceptance

Review final and final distribution publication using a Microsoft permission model




Corresponding author	[Redacted]
E-mail address	[Redacted]
Journal	International Journal of Pharmaceutics
Article number	121624
Our reference	IJP_121624
PII	S0378-5173(22)00179-X

Welcome [Redacted]

To help us finalize the publication of your article please complete the publishing form(s) below.

Note: you will receive a confirmation e-mail after completing each form.

 Information you may need to provide to complete the forms



Rights and Access

[Complete the rights and access form >](#)

Help and Support

[How you can share your article](#)



[Author rights information](#)

[A guide to publishing Open Access](#)

Corresponding author receives an email post acceptance with a unique link to complete the author journey and choose publishing options

Author clicks on Complete the Rights and Access information form



Rights and Access



- 1 Corresponding Author
- 2 Co-Author
- 3 Research Funders
- 4 Publishing Options
- 5 Licenses
- 6 Rights
- 7 Publishing Agreement
- 8 Review Order
- 9 Confirmation

Corresponding author selects his/her affiliation details which we use to identify the authors and match them to the Dutch consortium-Elsevier agreement

Please note that the author has already provided this information at submission; it is prepopulated

Corresponding author
 E-mail address
 Journal
 Our reference
 PII

Tell us the corresponding author's organization

Using the corresponding author's organization or institution, we will see if any publishing agreements apply, which can affect the price of publishing open access and who pays.

Select their main institution, not their department.


Organization name*

- University of Amsterdam
- University Of Amsterdam
Amsterdam, NL
- University of Professional Education Amsterdam
Amsterdam, NL
- Amsterdam University of Applied Sciences
Amsterdam, NL
- University of Amsterdam Amsterdam Business School
Amsterdam, NL
- University of Amsterdam Faculty of Law
Amsterdam, NL
- University of Amsterdam Amsterdam Law School
Amsterdam, NL
- University of Amsterdam Faculty of Medicine

Save and Continue >

All content on t
technologies.

All rights are reserved, including those for text and data mining, AI training, and similar



[Blurred dropdown menu]

Were there any co-authors for this article?

Yes

No

Add Co-author Details ⓘ

Please provide details for all co-authors. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

Hint: start the organization search using the main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find the specific department, then selecting the main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

First name or initial*	Last name*
John	Head

Organization name*


KU Leuven

Or use recently selected organization


[Blurred dropdown menu]

+ Add another co-author

Corresponding author also adds the co-author affiliation details



Author can add the Funder details. Funder can be the affiliated institution or a different one. In this case it is Milliman



Did the research in this article receive funding?

- Yes
 No

Funder Details ⓘ

Determine the best publishing options for your article. Please include the details about any funding received outside of your primary affiliations. If providing details for two or more organizations, please list the organization(s) that provided the most funding first.

For tips on searching for an organization please visit our [Support Center](#)

Organization name*

Milliman Inc



Grant/Contract numbers*

GT123



+ Add grant/contract number

+ Add another organization

Previous

Save and Continue >

- Based on the affiliation details, the author sees the Publishing Options. Gold OA option is the default option
- If the librarian/admin at the institution rejects the author request in the Elsevier Platform, we also make it clear that the authors will receive a full price invoice

Based on information you have provided, your publishing option is shown below

Open access

Publish as an open access article

Make my published article available to everyone.

As an author affiliated with the University of Amsterdam, upon validation, [the agreement between VSNU and Elsevier](#) will cover the APC. I and others can share and reuse my article in the ways described by the user license I select.

Please contact [OA Policy](#) for publishing subscription.


Institution preferred

Your institution prefers you publish OA

Article Publishing Charge (APC)

Price

EUR 3,980.00

 Institutional Agreement Discount

- 3,980.00

To pay (on validation)

 **0.00**

If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 4,360.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

[Dutch institutions and Elsevier Agreement](#)

Previous

Save and Continue >



- **System presents the author with the CC BY license with an option to opt for other licenses**

Select your user license

The following license will apply to the article:

CC BY 4.0

[For choosing an alternate license, please contact oapolicy@elsevier.com]

(Creative Commons Attribution 4.0 International License)

With this license, end users:


- can share all or part of the article in any medium or format for any purposes, even commercial.
- can share altered versions of your article for any purposes, even commercial. Learn more about permitted reuse under this license on [Elsevier's open access licenses page](#).
- must provide attribution (give credit) to the original article, include a link to the license, and indicate if changes were made.

Full details of the [CC-BY 4.0 license](#) are on the [Creative Commons website](#).

Note: this refers to end user rights. Your rights in your own work as an author are detailed in your publishing agreement and on [Elsevier's copyright page](#).

Previous

Save and Continue >



Author selects the rights

How best do you describe your organization? [View all options](#)

Elsevier B.V.

Select Your Status

- I am the sole author of the manuscript
 - I am one author signing on behalf of all co-authors of the manuscript
- Please indicate which of the below applies to you:
- We are all US Government employees and the Article is public domain and therefore the 'License of publishing rights' clause does not apply
 - I am a US Government employee but some of my co-authors are not
 - I am not a US Government employee but some of my co-authors are
 - The work was performed by contractors of the US Government under contract number:
- Contract Number* _____
- All or some of the authors are UK, Canadian or Australian Government employees and Crown Copyright is asserted
 - Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted
 - None of the above
- I am signing as an authorized representative and on behalf of my employer

Signed on Behalf of Corresponding Author

Please complete this section if you are not the corresponding author as listed above. A copy of the agreement will be sent to you and the corresponding author.

I am signing on behalf of the corresponding author

Name, job title and company (if employer representative)* _____

E-mail address* _____

Previous

Save and Continue >

1

Corresponding
Author

2

Co-Author

3

Research
Funders

4

Publishing
Options

5

Licenses

6

Rights

7

Publishing
Agreement

8

Payment
Details

9

Review Order

10

Confirmation



Elsevier B.V.

Your Status

- I am one author signing on behalf of all co-authors of the manuscript

License of Publishing Rights

I hereby grant to Elsevier B.V. an irrevocable non-exclusive license to publish, distribute and otherwise use all or any part of the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in all forms and media (whether now known or later developed) in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication.

I acknowledge the importance of the integrity, authenticity and permanence of the scholarly record and agree that the version of the Article that appears or will appear in the journal and embodies all value-adding publisher activities (including peer review co-ordination, copy-editing, formatting, (if relevant) pagination, and online enrichment) shall be the definitive final record of published research ("the Published Journal Article").

I further acknowledge and agree that nothing in this Agreement shall be deemed to permit redundant/duplicate publication of the Article in violation of publishing ethics principles, as further described below.

Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

**System presents author
with the Journal License
Publishing Agreement**

Author agrees to the Journal License Publishing Agreement

journal home page. For further information on sanctions, see <https://www.elsevier.com/about/our-business/policies/trade-sanctions> ↗

Author representations

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses which conflict with the terms of this License Agreement.
- If I and/or any of my co-authors reside in Russia, Belarus, Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See <https://www.elsevier.com/about/our-business/policies/patient-consent> ↗ for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier B.V. ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see <http://www.elsevier.com/copyright> ↗.

I have read and agree to the terms of the License Agreement.


9 February 2024

T-copyright license-v5/2017

Previous

Accept Agreement >

Rights and Access



Once the author clicks on Finish:

- Corresponding author and coauthors receive a copy of summary via email
- Article becomes OA on ScienceDirect within 24 hours
- Admin will receive a request within 48 hours
- Admin will validate the request within 3 weeks
- If the request is approved, the author will receive the full APC coverage
- If the request is rejected, the author can pay full price or choose to publish subscription



Review Order


Research Funders	Milliman Inc Grant numbers: GT123
Publishing Option	Gold Open Access
User License	CC BY 4.0
Publishing Agreement	<ul style="list-style-type: none"> I am one author signing on behalf of all co-authors of the manuscript and I am duly authorized to do so by all co-authors of the manuscript <p>I may share my final published article widely in accordance with the user License that I have selected. Further details on Elsevier Sharing Policy here.</p>


20 June 2024

[Previous](#)

Total payment due

Price (excluding taxes)
EUR 3,980.00

Institutional Agreement Discount
 - 3,980.00

To pay (on validation)
 **0.00**

If your institution cannot confirm your affiliation, you will receive a full price invoice for EUR 3,980.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

[Finish >](#)

Support for authors and librarians/admins

- Author queries – oasupport@elsevier.com
- Librarian/Admin queries, EOAP account set up or changes – agreementactivation@elsevier.com
- Author journey videos:
https://service.elsevier.com/app/answers/detail/a_id/29789/supporthub/publishing/track/APN2ZgoIDv8a~RNiGvwa~yKgpv0qOS75Mv9e~zj~PP_X/



Thank you

